- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02615847
Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients (MemSID)
A Phase II, Open Label, Single Center Trial to Study the Safety and Tolerability of Memantin Mepha® as Supportive Long Term Treatment in Symptomatic Sickle Cell Disease
Symptomatic sickle cell disease is worldwide the most frequent cause for hereditary hemolytic anemia with recurrent pain crisis. Hemolysis, vaso- occlusive and pain crises are hallmarks of this disease and are causative for an important socio-economic burden worldwide, especially in Africa.
Aside from allogenic stem cell transplantation, which is rarely available and very expensive, at present there is no curative treatment for patients with sickle cell disease (SCD). The current standard of care includes treatment with hydroxycarbamide and symptomatic care such as transfusions, antibiotic/analgesic treatment.
This study has the aim to study the safety and tolerability of Memantin in patients with sickle cell disease.
연구 개요
상세 설명
During the study participants will be asked if medical occurrences (AEs) happened and laboratory analysis (haematology, coagulation, chemistry) and urine samples will be taken. In addition at each visit a physical examination and measurement of vital signs will be performed.
In addition the number of hospital days and emergency consultations, the impact on working ability (the number of days with inability to work, changes in iv%), the amount and type of analgesic medication, the amount of RBC transfusions, the number of days that antibiotics prescribed and haematology (at local and external laboratory) and chemistry laboratory parameters will be assessed. For the impact on work and social life a questionnaire of quality of life will be filled out monthly by the patient.
At screening and at the end of the study SCD specific assessments will be performed, which include cardiologic examination (ECG, ECHO), abdominal sonography, ophthalmological examination, lung function testing and neuroangiologic examination.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Zürich, 스위스, 8091
- University Hospital Zurich
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Documented symptomatic sickle cell disease (HbSS or HbS/beta thalassemia)
- Age 18 years or older
- Able and willing to provide written informed consent and to comply with the study protocol procedures
- Willing to use two effective methods of contraception during study treatment until 6 months after stop of study treatment. Effective contraception methods are considered oral, injectable, implantative contraceptives or intrauterine contraceptive devices combined with the use of condom.
Exclusion Criteria:
History of transfusion during last three months before Screening
- Patients with active bacterial, viral or fungal infection requiring systemic treatment
- Patients with known infection with human immunodeficiency virus (HIV) of human T cell leukaemia virus 1 (HTLV-1)
- Inadequate renal function: creatinine clearance < 30ml/min
- Inadequate liver function: NCICTC Grade 3 liver function tests (AST, ALT > 5x upper limit of normal (ULN))
- History of malignancy
- Women who are pregnant or breast feeding
- Previous known mental disorder or known family history of psychiatric diseases
- Known epileptic disease
- The receipt of any investigational product within 30 days prior to this trial
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Memantin arm
Memantinhydrochlorid, administered once per day during 12 month.
Dosage is from 0-20 mg.
|
Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister. The study drug will be taken once a day per os, during 12 month.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Number of participants with treatment related adverse events as assessed by CTCAE version 4.0
기간: 14 month
|
14 month
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Haemoglobin in g/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Erythrocytes in T/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Reticulocytes in G/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Haptoglobin in g/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Billirubin in micmol/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
LDH (Lactat dehydrogenase) in U/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Ferritin in micg/l
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Transferrin saturation in %
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days in hospital
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days with inability to work
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of transfusions
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Number of days taken antibiotics
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Amount of pain medication in mg or ml
기간: 38 month
|
2 years before screening until end of study.
|
38 month
|
Pain scale
기간: 38 month
|
Scores range from 0 (no pain) to 10 (worst possible pain).
|
38 month
|
공동 작업자 및 조사자
수사관
- 연구 의자: Jeroen Goede, MD, UniversitätsSpital Zürich
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
겸상 적혈구 질환에 대한 임상 시험
-
Sandy SrinivasGlaxoSmithKline완전한방광암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전) | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성) | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능미국
-
Stanford UniversityNational Institutes of Health (NIH)빼는방광암 | 피부암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전)미국
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.모병미만성 거대 B세포 림프종 | 재발성 미만성 대형 B세포 림프종 | 난치성 미만성 대형 B세포 림프종 | 원발성 종격동(흉선) 대형 B세포 림프종 | 등급 3b 여포성 림프종 | 변형된 여포 림프를 Diff 대형 B-세포 림프종으로 | 변형된 마그 존 림프를 Diff Large B-Cell Lymphoma로미국
-
University of Alabama at Birmingham종료됨역형성 대세포 림프종 | 혈관면역모세포성 T세포 림프종 | 말초 T 세포 림프종 | 성인 T 세포 백혈병 | 성인 T 세포 림프종 | 상세불명의 말초 T 세포 림프종 | T/Null Cell 전신형 | 림프절/내장 질환을 동반한 피부 T세포 림프종미국